Tirzepatide

Dual GIP / GLP-1 receptor agonist

MetabolicGrade A — Strong human evidenceFDA-approvedMounjaro · Zepbound

A dual agonist hitting both the GIP and GLP-1 receptors. Head-to-head trials show greater average weight reduction than single-agonist GLP-1s, at the cost of a similar gastrointestinal side-effect profile.

REGULATORY STATUS · FDA-APPROVED

FDA-approved (Mounjaro, Zepbound).

§ EVIDENCE BASE

listing it as an intervention

161

PHASE 2–4 TRIALS

reached later-stage testing

MECHANISMDual GIP / GLP-1 receptor agonist

CATEGORYMetabolic

EVIDENCE GRADEA — Strong human evidence

STATUSFDA-approved (Mounjaro, Zepbound)

TYPICAL RECONSTITUTION10 mg vial + 2 mL BAC water

ROUTESubcutaneous — abdomen, thigh or upper arm

COUNTS RETRIEVED2026-07-23 · re-run the PubMed query

§ DOCUMENTED DOSING

Weeks 1–42.5 mg once weekly

Weeks 5–85 mg once weekly

Then titrate7.5 → 10 → 12.5 mg as tolerated

Maximum15 mg once weekly

Ranges compiled from published protocols, not a clinical guideline. Convert a dose into syringe units with the dosage calculator.

§ RELATED COMPOUNDS

METABOLICA

Semaglutide

GLP-1 receptor agonist

METABOLICC

Retatrutide

Triple GIP / GLP-1 / glucagon receptor agonist

METABOLICD

AOD-9604

hGH fragment 176-191; lipolytic activity (proposed)

NOT MEDICAL ADVICE

This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.

Onpeps

Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.

EXPLORE

Home Peptide Library About Blog Peptide Vendors Research Tools

Instagram LinkedIn Spotify

Tirzepatide

Peptide intelligence, every Monday.